485-23-4

Basic information

• Product Name: N-(2,7-dihydroxy-8-methyl-4-oxo-4H-chromen-3-yl)-4-hydroxy-3-(3-methylbut-2-en-1-yl)benzamide
• CAS NO: 485-23-4
• Molecular Formula: C₂₂H₂₁NO₆
• Molecular Weight: 395.4052
• Mol File: 485-23-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 667.6°C at 760 mmHg
• Flash Point: 357.6°C
• Density: 1.42g/cm³
• Vapor Pressure: 9.82E-19mmHg at 25°C
• Refractive Index: 1.679
• CAS DataBase Reference: N-(2,7-dihydroxy-8-methyl-4-oxo-4H-chromen-3-yl)-4-hydroxy-3-(3-methylbut-2-en-1-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,7-dihydroxy-8-methyl-4-oxo-4H-chromen-3-yl)-4-hydroxy-3-(3-methylbut-2-en-1-yl)benzamide(485-23-4)
• EPA Substance Registry System: N-(2,7-dihydroxy-8-methyl-4-oxo-4H-chromen-3-yl)-4-hydroxy-3-(3-methylbut-2-en-1-yl)benzamide(485-23-4)

Safety Data

• Hazardous Substances Data: 485-23-4(Hazardous Substances Data)

Upstream product

• 1476-53-5 sodium novobiocin 
• 303-81-1 novobiocin 
• 56971-02-9 3-amino-4,7-dihydroxy-8-methyl-2H-chromen-2-one 
• 1138-41-6 4-hydroxy-3-prenylbenzoic acid 
• 3780-29-8 4,7-dihydroxy-3-amino-8-methylcoumarin hydrochloride 
• 92194-92-8 4-(chlorocarbonyl)-2-(3-methylbut-2-en-1-yl)phenyl acetate 

Downstream Products

• 1348829-25-3 C₂₅H₂₇NO₆ 
• 1990-85-8 4-acetoxy-3-(3-methylbut-2-en-1-yl)benzoic acid 
• 3780-30-1 7-acetoxy-2,6-dimethyl-chromeno[3,4-d]oxazol-4-one 

Relevant articles and documents

Novobiocin Enhances Polymyxin Activity by Stimulating Lipopolysaccharide Transport

Gram-negative bacteria are challenging to kill with antibiotics due to their impenetrable outer membrane containing lipopolysaccharide (LPS). The polymyxins, including colistin, are the drugs of last resort for treating Gram-negative infections. These drugs bind LPS and disrupt the outer membrane; however, their toxicity limits their usefulness. Polymyxin has been shown to synergize with many antibiotics including novobiocin, which inhibits DNA gyrase, by facilitating transport of these antibiotics across the outer membrane. Recently, we have shown that novobiocin not only inhibits DNA gyrase but also binds and stimulates LptB, the ATPase that powers LPS transport. Here, we report the synthesis of novobiocin derivatives that separate these two activities. One analog retains LptB-stimulatory activity but is unable to inhibit DNA gyrase. This analog, which is not toxic on its own, nevertheless enhances the lethality of polymyxin by binding LptB and stimulating LPS transport. Therefore, LPS transport agonism contributes substantially to novobiocin-polymyxin synergy. We also report other novobiocin analogs that inhibit DNA gyrase better than or equal to novobiocin, but bind better to LptB and therefore have even greater LptB stimulatory activity. These compounds are more potent than novobiocin when used in combination with polymyxin. Novobiocin analogs optimized for both gyrase inhibition and LPS transport agonism may allow the use of lower doses of polymyxin, increasing its efficacy and safety.

HOMODIMERIC TOBRAMYCIN ADJUVANT REPURPOSES NOVOBIOCIN AS AN EFFECTIVE ANTIBACTERIAL AGENT AGAINST GRAM-NEGATIVE BACTERIA

Low permeability across the outer membrane is a major reason why most antibiotics are ineffective against Gram-negative bacteria. Agents that permeabilize the outer membrane are typically toxic at their effective concentrations. Here, we report the develo

AUTOPHAGY INHIBITORS

A compound, which is a) a tetrahydrotriazine derivative of the formula (I), a tautomer, a pharmaceutically acceptable salt, a solvate or hydrate thereof, were the symbols have the meanings given in the description, or b) a coumarin derivative of the formula (II), a tautomer, a pharmaceutically acceptable salt, solvate or hydrate thereof, were the symbols have the meanings given in the description, is useful in a therapeutical method for inhibiting autophagy in a cell and for the treatment of cancer.